Applied DNA Sciences Signs Business Development and Trademark License Agreement with Dr. Suwelack Skin & Healthcare AG

May 09, 2006, 01:00 ET from Applied DNA Sciences, Inc.

    STONY BROOK, N.Y., May 9 /PRNewswire-FirstCall/ -- Applied DNA
 Sciences, Inc. (OTC Bulletin Board:   APDN), a DNA security solutions
 company, announced that it signed an agreement with Dr. Suwelack Skin &
 Healthcare AG ("Suwelack") providing Suwelack rights to use APDN's
 SigNature(TM) logo, which is printed with ink containing our proprietary
 encrypted botanical DNA technology, and to participate in its SigNature(TM)
 Program. The terms of this one year license agreement provide Suwelack with
 a limited, non-exclusive, non-transferable right to use the SigNature(TM)
 logo on its packaging and labels.
     Created by APDN, the goal of the SigNature(TM) Program is to provide a
 secure, cost effective and forensic method to help companies like Suwelack
 protect their intellectual property assets and the value of their brand.
 This program is based on APDN's proprietary platform technology whereby
 nanoscopic botanical DNA is embedded in a proprietary protective coating
 that withstands commercial processing and gives DNA a life of several
 hundred years. Botanical DNA will be embedded into the ink that will be
 used in the SigNature(TM) logo utilizing both overt and covert DNA security
 technologies. This botanical DNA can later be sequenced and decoded from
 the SigNature(TM) logo to verify the authenticity of Suwelack's products.
     Suwelack is recognized in Germany as the leader in the innovation,
 development and manufacture of biomatrices for cosmeceutical and healthcare
 applications. Suwelack has adopted the SigNature(TM) Program as one of many
 new initiatives that complement its expansion into the North American
     According to Nikolaus Uleer, Chief Executive Officer of Suwelack, "We
 are very pleased to utilize DNA encryption technology in our packaging. It
 provides a secure, forensic, and most importantly, cost effective approach,
 that we believe will provide a positive contribution to the development of
 our brand."
     The SigNature(TM) Program is the first initiative by APDN to introduce
 to the market a range of ready-to-use security solutions aimed at brand
 protection and authentication, and addressing the global need to combat
 counterfeit and piracy.
     Dr. Benjamin Liang, Chief Scientist of Applied DNA Sciences, said, "We
 believe that our technology provides an immediate benefit and relevance to
 a company like Suwelack that has applications in both skincare and
 healthcare. From a business development perspective, we can deliver a
 fast-track security solution intended to provide both strategic and
 tactical value to our clients. We are pleased that Suwelack is our first
 commercial partner in Europe."
     About Dr. Suwelack Skin & Healthcare AG
     Dr. Suwelack Skin & Healthcare AG manufactures biomatrices for skin and
 healthcare for cosmeceutical and medical applications. Suwelack's patented
 technology uses a freeze-drying process to gently extract water from
 natural raw materials, as a result of which the raw materials are preserved
 in a highly pure form. By using this technique the company is able to avoid
 using preservative agents, chemical cross-linking agents and perfumes and
 ensure the basis for skin compatibility.
     About Applied DNA Sciences, Inc.
     Applied DNA Sciences, Inc. (APDN) develops proprietary DNA-embedded
 security solutions that use plant DNA to verify authenticity and protect
 corporate and government agencies from counterfeiting, fraud, piracy,
 product diversion, identity theft and unauthorized intrusion into physical
 plant and databases. Our common stock is listed on the Over-The-Counter
 Bulletin Board under the symbol "APDN".
     The statements made by Applied DNA Sciences, Inc. in this press release
 may be forward-looking in nature and are made pursuant to the safe harbor
 provisions of the Private Securities Litigation Reform Act of 1995. Such
 forward-looking statements describe the Company's future plans,
 projections, strategies and expectations, and may be identified by words
 such as "expects," "anticipates," "intends," "plans," "believes," "seeks,"
 "estimates" or words of similar meaning. These forward-looking statements
 are based on assumptions and involve a number of risks, uncertainties,
 situations and other factors that may cause our or our industry's actual
 results, level of activity, performance or achievements to be materially
 different from any future results, level of activity, performance or
 achievements expressed or implied by these statements. These factors
 include changes in interest rates, market competition, changes in the local
 and national economies, and various other factors detailed from time to
 time in Applied DNA Sciences' SEC reports and filings, including our Annual
 Report on Form 10-KSB, filed on January 12, 2006, and subsequent Quarterly
 Reports on Form 10-QSB and Current Reports on Form 8-K. The Company
 undertakes no obligation to update publicly any forward-looking statements
 to reflect new information, events or circumstances after the date hereof
 to reflect the occurrence of unanticipated events.

SOURCE Applied DNA Sciences, Inc.